Atai Life Sciences N.V.
ATAI
Atai Life Sciences N.V., through its subsidiary, ATAI Life Sciences AG, operates as a clinical-stage biopharmaceutical company. It engages in developing various therapeutic candidates that focuses on various mental health disorders. The company's therapeutic candidates include PCN-101, a subcutaneous formulation of R-ketamine for the treatment of treatment-resistant depression (TRD); RL-007, a choā¦ read more
Healthcare
Biotechnology
5 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$7.29
Price+0.14%
$0.01
1Y
Price
Market Cap
$2.697b
Mid
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financial Reports
Key metrics over the past few years and other important metrics. Amounts in USD.-2577.8%
EBITDA Margin-1908.7%
Net Profit Margin-2070.0%
Free Cash Flow Margin-2577.8%
EBITDA Margin-1908.7%
Net Profit Margin-2070.0%
Free Cash Flow MarginRevenue
$4.473m
+9.4%
1y CAGR+411.7%
3y CAGR+317.5%
5y CAGREarnings
-$668.193m
-1.2%
1y CAGR-204.8%
3y CAGR-135.2%
5y CAGREPS
-$2.90
+0.3%
1y CAGR-161.5%
3y CAGR-102.5%
5y CAGRBook Value
$176.437m
$264.793m
Assets$88.356m
Liabilities$4.285m
DebtDebt to Assets
1.6%
-
Debt to EBITDAFree Cash Flow
-$133.241m
-28.6%
1y CAGR-17.2%
3y CAGR-8.0%
5y CAGRNo items found.
Press Releases
Statements and updates from the company